452056-80-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-(2-Aminopyridin-4-yl)-2-(4-fluorophenyl)-ethanone is utilized as a key intermediate in the synthesis of pharmaceutical drugs and other organic compounds. Its unique structure and properties contribute to its potential as a drug candidate, offering opportunities for the development of novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(2-Aminopyridin-4-yl)-2-(4-fluorophenyl)-ethanone is employed as a building block for the design and synthesis of new compounds with potential biological activity. Its presence in various chemical libraries allows researchers to explore its interactions with biological targets and evaluate its efficacy in treating specific diseases.
Used in Pharmacology:
1-(2-Aminopyridin-4-yl)-2-(4-fluorophenyl)-ethanone is also used in pharmacological studies to investigate its potential therapeutic properties. Researchers are interested in understanding how 1-(2-AMinopyridin-4-yl)-2-(4-fluorophenyl)-ethanone interacts with biological systems and its potential role in the treatment of various conditions, including diseases that currently lack effective treatments.

Upstream product

• 5327-32-2 2-acetylamino-4-methylpyridine 
• 695-34-1 2-Amino-4-methylpyridine 
• 459-22-3 4-fluorophenylacetonitrile 
• 452056-79-0 N-{4-[2-cyano-2-(4-fluorophenyl)acetyl]pyridin-2-yl}acetamide 
• 549505-57-9 N-{4-[2-cyano-2-(4-fluoro-phenyl)-1-hydroxy-vinyl]-pyridin-2-yl}-acetamide 

Downstream Products

• 908382-42-3 2-(4-fluorophenyl)-1-(2-fluoro-4-pyridyl)ethanone 
• 549505-58-0 N-{4-[4-(4-fluorophenyl)-1-methyl-2-methylsulfanyl-1H-imidazol-5-yl]pyridin-2-yl}-N-(1-phenylethyl)amine 
• 452056-98-3 4-[4-(4-fluorophenyl)-1-methyl-2-methylsulfanyl-1H-imidazol-5-yl]pyridin-2-ylamine 
• 452056-93-8 N-{4-[4-(4-fluorophenyl)-1-methyl-2-methylsulfanyl-1H-imidazol-5-yl]pyridin-2-yl}acetamide 
• 820241-52-9 4-[5-(2-acetylaminopyridin-4-yl)-4-(4-fluorophenyl)-2-thioxo-2,3-dihydroimidazol-1-yl]piperidin-1-carbonic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases

The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors was coincidentally expanded to a dual inhibition of p38α MAPK and phosphodiesterase 4 (PDE4), and the potential benefits arising from the blockage of both inflammation-related enzymes were thoroughly investigated. The most promising compound, CBS-3595 (1), was successively evaluated in in vitro experiments as well as in ex vivo and in vivo preclinical studies after administration of 1 to rodents, dogs, and monkeys. The resulting data clearly indicated a potent suppression of tumor necrosis factor alpha release. For reconfirming the findings of the animal studies when administering 1 to healthy human volunteers, a phase I clinical trial was conducted. Apart from further information regarding the pharmacokinetic and pharmacodynamic characteristics of 1, it was demonstrated that dual inhibition of p38α MAPK and PDE4 is able to synergistically attenuate the excessive anti-inflammatory response.

Imidazole compounds having an antiinflammatory effect

The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula I in which the radicals R1, R2, R3 and R4 have the meaning indicated in the description. The compounds of the i

2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS

The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula (I) in which the radicals R1, R2, R3 and R4 have the meaning indicated in the description. The compounds of the

Tetrasubstituted imidazole inhibitors of cytokine release: Probing substituents in the N-1 position

We prepared novel 1,2,4,5-tetrasubstituted imidazole derivatives with high anti-inflammatory activity by using our previously described regiospecific synthesis. Systematic optimization of the imidazole N-1 substituent resulted in compound 9b that potently

Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR

The regiospecific synthesis of 2a (Scheme 3), a novel and potent pyridinyl imidazole inhibitor of p38 MAP (mitogen-activated protein) kinase, and the regioselective preparation of its regioisomer 2b (Scheme 4) are described. Chromatographic and spectroscopic data are presented, which in this class of compounds allow the unambiguous identification of regioisomers prepared by a nonregiospecific synthetic strategy. Biological data demonstrating the importance of the correct regiochemistry for inhibition of p38 are given.